PT - JOURNAL ARTICLE AU - Ahmed Shamekh AU - Colin Powell AU - Abdusamea Ashabani AU - Ibtihal Siddiq Abdelgadir TI - Post-COVID mRNA vaccine myocarditis in children: report of two cases AID - 10.1136/bcr-2022-253383 DP - 2022 Nov 01 TA - BMJ Case Reports PG - e253383 VI - 15 IP - 11 4099 - http://casereports.bmj.com/content/15/11/e253383.short 4100 - http://casereports.bmj.com/content/15/11/e253383.full SO - BMJ Case Reports2022 Nov 01; 15 AB - The SARS-COV-2 pandemic led to the development of several vaccinations to contain the disease. The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine was recommended on May 2021 for use in children above 12 years and older. The vaccine is safe, well tolerated and highly effective. Initial reports showed no serious adverse events; however, cases of myocarditis in young healthy male adolescents have been reported. We report two cases of myocarditis/perimyocarditis who presented with short history of chest pain following administration of the second dose of the MRN COVID-19 vaccine.